Nilotinib

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board

Retrieved on: 
火曜日, 2月 27, 2024
Rubius, Odyssey, Senior, Inborn errors of metabolism, Investment, Drug development, Growth, Sale, IPO, University, Intuitive Surgical, Neurodegenerative disease, Analog Devices, National academy, J. P. Morgan, MIT, Genetic distance, American Philosophical Society, Business development, Journal, Therapy, Imatinib, SRL Diagnostics, MidOcean Partners, Distinction, Laboratory, Cornell University, Drug discovery, Weill Cornell Medicine, Provost, Panasonic Executive Partner, Abbott Laboratories, Flagship, Novartis, Medtronic, MACP, Harvard Medical School, Nilotinib, American Academy, Yale School of Medicine, JPMorgan Chase, AI, MD, Flagship Pioneering, Harvard University, MassMutual, Executive, Cancer, Management

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.
  • Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team.
  • The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management.
  • The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors.

Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Retrieved on: 
木曜日, 1月 25, 2024
Hope, Leukemia, Research, Drug resistance, Collection, SAN, SVS, Workflow, Genomics, ODL, Cell, FDA, Doctor of Philosophy, Nilotinib, OGM, Pharmaceutical industry

The publication describes what could be the first study to use optical genome mapping (OGM) for the discovery of structural variants (SVs) that drive drug resistance and sensitivity in cancer.

Key Points: 
  • The publication describes what could be the first study to use optical genome mapping (OGM) for the discovery of structural variants (SVs) that drive drug resistance and sensitivity in cancer.
  • The study analyzed 26 leukemia samples from 23 subjects, including 3 samples from subjects after relapse.
  • The study used a cell viability and drug screening assay based on growing leukemia-enriched cell collections in the presence of different concentrations of drug agents to measure cell viability.
  • Overall, the study shows that OGM for SV detection combined with drug sensitivity data for the same samples is a useful approach to identifying potentially pathogenic SVs that may be drivers of drug sensitivity or resistance.

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP

Retrieved on: 
水曜日, 12月 13, 2023
Hydroxycarbamide, Research, Intolerance, Dasatinib, HHT, Aes, Incidence, ASH, Risk, NMPA, TKI, Eastern Cooperative Oncology Group, Hematology, Disease, Hospital, Patient, Nilotinib, QOD, Pacific Time Zone, BCR, Pacific Ocean, CHB, Prognosis, Natural product, ECOG, Cancer, CML, Death, R, Hepatitis, Society, Notifiable disease, BAT, HIV disease progression rates, Pharmaceutical industry, Nursing, EFS

This is the sixth consecutive year in which study results on olverembatinib have been selected for Oral Presentations at the ASH Annual Meeting.

Key Points: 
  • This is the sixth consecutive year in which study results on olverembatinib have been selected for Oral Presentations at the ASH Annual Meeting.
  • After reaching EFS, patients in the BAT arm were allowed to cross-over to the olverembatinib arm for continued treatment.
  • Patients: As of October 17, 2023, a total of 144 patients were enrolled, of whom 96 patients received olverembatinib and 48 received BAT.
  • In addition, the olverembatinib arm has shown a higher cumulative response rate and longer duration of responses.

Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

Retrieved on: 
金曜日, 11月 24, 2023
NDA, Bone marrow, Priority review, Safety, National Medical Products Administration, BAT, Leukemia, EFS, New Drug Application, NMPA, TKI, CDE, Patient, BTD, Imatinib, Trust, Nilotinib, Therapy, BCR-ABL, CML, Death, Survival, NRDL, Government, Mutation, HIV disease progression rates, Pharmaceutical industry

Patients were randomized to either receive olverembatinib or into the control group to receive the current best available treatment (BAT).

Key Points: 
  • Patients were randomized to either receive olverembatinib or into the control group to receive the current best available treatment (BAT).
  • Olverembatinib is a global best-in-class novel drug developed by Ascentage Pharma with support from the National Major New Drug Discovery and Manufacturing Program in China.
  • Ascentage Pharma and Innovent are mutually committed to the commercialization of olverembatinib in the China market.
  • Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting

Retrieved on: 
火曜日, 11月 7, 2023
PD, US, BTD, TGCT, Priority, Human, European Medicines Agency, IDMC, Male, Liver injury, Hip, BIRC, Ankle, PRO, Pain, IRC, Completeness, Part Two, Response evaluation criteria in solid tumors, QD, 1.1, MRI, Itch, AST, US FDA, CSF1, Motion, Rash, Neoplasm, Independent Review Committee, PK, ORR, Part, Safety, Therapy, ALT, Patient, LDH, ASCO, PDGFR, Contraindication, Nilotinib, III, DOR, Imatinib, Breakthrough therapy, Clinical trial, Hepatotoxicity, Knee, FDA, Dyslipidemia, CPK, RES, SD, RECIST, Pharmaceutical industry, Nursing

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.

Key Points: 
  • SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.
  • The two clinical updates include reporting the design of the pivotal global multi-center phase III clinical trial and the further update of the phase Ib clinical trial of pimicotinib.
  • In 2023, the U.S. FDA conferred Breakthrough Therapy Designation and the European Medicines Agency granted Priority Medicine Designation upon Pimicotinib treatment of TGCT.
  • Here, we report the phase 1b safety and efficacy results of Pimicotinib in TGCT patients over a 1-year follow-up.

Global Myeloproliferative Disorders Drugs Research Report 2023: Market is Expected to Surpass $10.5 Bn in 2027 - Focus on JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate - ResearchAndMarkets.com

Retrieved on: 
木曜日, 10月 5, 2023
Biotechnology, Pharmaceutical, Health, Incidence, Imago, Bristol Myers Squibb, Nilotinib, Pancreatic serous cystadenoma, Primary myelofibrosis, FDA, Ageing, Radiation exposure, Merk, Growth, Bone marrow, Polycythemia, DSM-IV codes, Chronic myelogenous leukemia, Foundation for the National Institutes of Health, Pharmaceutical industry

The "Myeloproliferative Disorders Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myeloproliferative Disorders Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • In the rapidly advancing pharmaceutical landscape, the significance of myeloproliferative disorder drugs is more pronounced than ever.
  • Driving the surge in the market for these drugs is the escalating incidence of myeloproliferative disorders.
  • The countries covered in the myeloproliferative disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Retrieved on: 
月曜日, 8月 7, 2023
American literature, Drug development, Faculty of Tropical Medicine, Mahidol University, Therapy, Nilotinib, Decoy, Business administration, Hospital, Novartis, Patient, Columbia Business School, Brown University, Immunotoxin, Pharmaceutical industry

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D.

Key Points: 
  • NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D.
  • as its Chief Medical Officer, effective August 7, 2023.
  • Jeffrey Meckler, Indaptus’ CEO commented, “Roger’s deep experience in drug development, particularly in the field of immuno-oncology, and his time as an officer at development and clinical-stage companies makes him an ideal candidate to assume the position of chief medical officer at Indaptus.
  • Prior, he served in the c-suite as Chief Medical Officer at Rgenix, Inc. (now Inspirna, Inc) and as Chief Scientific Officer at Jaguar Health.

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
木曜日, 10月 20, 2022
Selection, Congress, Use, Medicine, Development, UICC, Non-communicable disease, Union, Essential medicines, Novartis, Sustainability, EOI, Patient, Private sector, Research, Access, MPP, Cancer, WHO, EML, Union for International Cancer Control, Nilotinib, World, WHO Model List of Essential Medicines, B cell, WHO Expert Committee on Leprosy, Agency, CML, SDC, Prognosis, Unitaid, Global Health, Coalition, Acute leukemia, Medicines Patent Pool, ATOM, Pharmaceutical industry, Medical imaging, Developing country

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
木曜日, 10月 20, 2022
Selection, Congress, Use, Medicine, Development, UICC, Non-communicable disease, Union, Essential medicines, Novartis, Sustainability, EOI, Patient, Private sector, Research, Access, MPP, Cancer, WHO, EML, Union for International Cancer Control, Nilotinib, World, WHO Model List of Essential Medicines, B cell, WHO Expert Committee on Leprosy, Agency, CML, SDC, Prognosis, Unitaid, Global Health, Coalition, Acute leukemia, Medicines Patent Pool, ATOM, Pharmaceutical industry, Medical imaging, Developing country

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

Gastrointestinal Stromal Tumors Drug Pipeline Market Report 2022: Comprehensive Insights About 25+ Companies and 28+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
火曜日, 10月 11, 2022
Research, Packaging, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, News, Disease, Therapy, DXD, NDA, Chronic myelogenous leukemia, Patient, Stromal cell, Cell proliferation, KIT, GIST, Technology, Cancer, III, Daiichi Sankyo, Nilotinib, Discovery, Acquisition, Jiangsu Hengrui Medicine, CML, Adult, Gastrointestinal stromal tumor, ADC, Clinical trial, PDGF, Medical imaging, Pharmaceutical industry, Fine chemical

The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022," report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape.

Key Points: 
  • The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022," report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape.
  • The assessment part of the report embraces, in depth Gastrointestinal Stromal Tumors commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumors R&D.
  • The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e.